This episode features excerpts from an interview with Dr Holbrook Kohrt who was leading the way in researching the potential of immune agonists targeting 4-1BB (CD137). It is with great sadness that we must report that since this episode aired, Holbrook Kohrt is no longer with us. He died, aged 38, on February 24, 2016.
In-Memorium Holbrook Kohrt
In memory of Holbrook Kohrt, a remarkable colleague and friend. Read more of his story: https://t.co/HqiyD8B2A9
— Marcel van den Brink (@DrMvandenBrink) February 24, 2016
The NYT obituary for Dr. Holbrook Kohrt, a hemophiliac who made his condition a crusade for medical cures https://t.co/gpYXKRpI1A
— NYT Health (@NYTHealth) March 1, 2016
Immune modulators come in two flavors – the much discussed checkpoint inhibitors that we featured in Episode 1 “The Checkpoints Show” are inhibitory and “release the brake,” while immune agonists are stimulatory and help to “step on the gas” and make the immune system more effective.
In addition to introducing the concept of immune agonists, this episode seeks to take our journey forward by discussing how they may be used in combination. You’ll hear again from Dr Tom Gajewski (Chicago), who you may recall from Episode 2 “The Immune Biomarker Show.”
Also featured in Episode 6, is Dr William Pao (Roche) who describes the company’s T cell focused strategy and how they segment new products into T cell effectors, modulators and generators.
You may recall hearing a “vignette” or mini-interview with Dr Pao in Episode 3 “ASCO Lung Cancer Show.”
There’s also an excerpt from an interview with Prof Tom Powles (Barts) on checkpoint inhibitors in bladder cancer. Potentially practice-changing data for atezolizumab in metastatic bladder cancer and nivolumab in renal cell carcinoma is expected at the forthcoming European Cancer Congress.
The interviews on the podcast were originally published on Biotech Strategy Blog (subscription required) and are excerpted on the podcast with permission.
Holbrook Kohrt: “Holbrook Kohrt leads the way in Targeting CD137”
The music in this podcast episode is by electric violinist and composer David Schulman from his album Quiet Life Motel.
Genentech sponsored this episode of Novel Targets – we’re grateful for their support!
Instead of a formal advertisement or reading a corporate message, we offer listeners mini interviews or vignettes with scientists and physicians to showcase their research.
In this episode, we featured Dr Deepak Sampath from Genentech who talked about his research into the combination of obinutuzumab with venetoclax.
This is an excerpt of an interview we did at the 2013 EORTC-NCI-AACR Molecular Targets meeting in Boston where Dr Sampath presented a poster.
You can find a transcript of the full interview on Biotech Strategy Blog (sub req’d): “Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath.”
© Blue Ice Publishing LLC. All Rights Reserved.